This study aims to evaluate in clinical practice the efficacy and safety of remdesivir in patients admitted for COVID-19
Description of the Study:
- Title: Real-life use of remdesivir in hospitalized patients with COVID-19.
- Principal Investigators: Carolina Garcia-Vidal, Fernanda Meira, Alberto Cózar-Llistó, Gerard Dueñas, Pedro Puerta-Alcalde, Nicole Garcia-Pouton, Mariana Chumbita, Celia Cardozo, Marta Hernandez-Meneses, Rodrigo Alonso-Navarro, Verónica Rico, Daiana Agüero, Marta Bodro, Laura Morata, et al.
- Centres of Implementation: Hospital Clínic of Barcelona.
- Study Population: Patients hospitalised for more than 48 hours with severe COVID-19.
- Study Type: Observational cohort study.
- Design: A total of 123 of the 242 patients admitted with COVID-19 received remodivir.
- Methods: A descriptive study was conducted of all patients admitted for ≥48 hours with confirmed COVID-19 who received remdesivir between 1 July and 30 September 2020.
Objectives of the Study:
Principal Objective: Controversial results have been reported on the efficacy of remdesivir, so the aim of this study is to report the real-life experience with the use of remdesivir since its availability in Spain.
More about this Study:
Conclusions: In their actual experience, the use of remdesivir in hospitalised patients with COVID-19 was associated with a low mortality rate and a good safety profile.
Scientific Context: On May 1st, 2020, remdesivir received Food and Drug Administration (FDA) emergency use authorization for hospitalized patients with COVID-19 and was officially approved on October 22nd, 2020. Initial clinical trials using a control arm demonstrated the superiority of remdesivir in terms of clinical status improvement at day 28 or at day 11; however, initial clinical trials performed in China and a recent report from the Solidarity trial did not prove that remdesivir had no benefit. Different outcomes and the potential influence of when remdesivir was administered after symptom onset could explain the apparently controversial results in the aforementioned trials.
Other Studies About Pharmacology:
Collaborez avec l’étude ANTICOV et contribuez à traiter la COVID-19 en Afrique.
Est-ce que les hormones sexuelles peuvent aider les hommes survivre le COVID-19 ? Cette étude a pour objectif évaluer la sécurité et l’efficacité de la progestérone dans le traitement de COVID-19 chez les hommes hospitalisés.
This study aims to demonstrate efficacy of Montelukast for patients with persistent COVID-19 to help them improve their quality of life.
CIBERES UCI COVID is a fundamental study that will improve care of critical patients infected by COVID-19.
This study aims to determine the effects of vaccination against SARS-CoV-2 in people with long COVID.
Antimicrobial stewardship approaches urgently need to be reinforced during the COVID-19 pandemic. This study evaluates the impact of the COVID-19 on antibiotic consumption.
This study suggests that primary care diagnosis and treatment with antihistamines, plus azithromycin in selected cases, may treat COVID-19 and prevent progression to severe disease in elderly patients.
Clinical trial to perform immunomodulatory treatment in adult patients with severe COVID-19 pneumonia with the aim of helping to define the standard treatment for this disease.
This multicentre clinical trial aims to demonstrate that treatment with Calcifediol reduces the need for invasive ventilation and Intensive Care Unit admissions and deaths.
Phase II clinical trial evaluating the safety and efficacy of the drug Maraviroc combined with standard therapy versus standard therapy in patients infected with SARS-CoV-2 and hospitalised with COVID-19.